Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis

Danielle Benedict Sacdalan1
Josephine Anne Lucero2
Dennis Lee Sacdalan1

1Section of Medical Oncology, Department of Medicine, University of the Philippines Manila and Philippine General Hospital, Manila, Philippines; 2Department of Medicine, University of the Philippines Manila and Philippine General Hospital, Manila, Philippines

Introduction: Systemic inflammation is associated with prognosis in solid tumors. The neutrophil-to-lymphocyte ratio (NLR) is a marker for the general immune response to various stress stimuli. Studies have shown correlation of NLR to outcomes in immune checkpoint blockade, peripheral neutrophil count to intratumor neutrophil population, and NLR to intratumoral levels of myeloid-derived suppressor cells. Studies have shown elevated peripheral blood regulator T cells accompanied by elevated NLR are associated with poor outcomes further highlighting the importance of inflammation in the prognosis of cancer patients.

Methods: We performed a meta-analysis of published articles on the utility of baseline NLR in predicting outcomes in patients treated with immune checkpoint inhibitors (ICIs) using Review Manager, version 5.3. Seven studies on the prognostic utility of NLR in ICI treatment were included in this analysis. For outcomes of interest, the hazard ratios (HRs) were computed. Subgroup analyses were planned based on type of malignancy and type of immune checkpoint inhibitor.

Results/discussion: A high NLR resulted in worse overall survival (OS) (HR, 1.92; 95% CI, 1.29–2.87; p=0.001) and progression-free survival (PFS; HR, 1.66; 95% CI, 1.38–2.01; p<0.00001) across types of malignancies studied (melanoma, non-small-cell lung cancer, and genitourinary cancer). Subgroup analysis across different types of malignancies treated with ICI showed similar results for OS and PFS. The single study on genitourinary cancers also showed worse OS and PFS (OS: HR, 1.82; 95% CI, 1.29–2.87; p=0.001 and PFS: HR, 1.83; 95% CI, 0.97–3.44; p=0.06). A high NLR also showed worse OS and PFS across all ICIs (ipilimumab, nivolumab, and unspecified or pooled pembrolizumab and nivolumab; OS: HR, 1.92; 95% CI, 1.29–2.87; p=0.001 and PFS: HR, 1.66; 95% CI, 1.38–2.01; p<0.00001). Subgroup analysis by type of ICI showed similar results.

Conclusion: A high NLR is associated with poorer outcomes across studies. This shows that NLR has the potential as a readily available prognostic indicator for patients receiving ICI based on available studies. Studies utilizing more stringent design may serve to better determine the utility of this tool.

Keywords: neutrophil-to-lymphocyte ratio, immunotherapy, biomarkers, inflammation

Introduction
An increasing interest has followed immunologic checkpoint blockade beginning with the approval of the first agent, ipilimumab. As studies continue to show notable and durable response to checkpoint inhibition across different indications, the search for biomarkers that will predict response to therapy has gained pace. In addition, the role of inflammation in cancer immunology and its effect on cancer immunotherapy merits scrutiny. Studies have shown consistently that inflammation is associated with...
prognosis in solid tumors due to its effect on the immune response to the disease. Specifically, the association between inflammation and immunosuppression, which is one of the hallmarks of cancer, is pointed out. In this context, different biomarkers have been investigated in predicting response to immune checkpoint blockade apart from programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). These biomarkers include professional immunoregulatory cells, soluble mediators such as adenosine, and neutrophil-to-lymphocyte ratio (NLR).

CTLA-4 and PD-1/PD-L1

The regulation of effector T-cell function underpins the host immune response to self- versus non-self-antigens. Binding of the T-cell receptor (TCR) to a major histocompatibility complex (MHC)-bound antigen on an antigen-presenting cell (APC) is the determinant of its subsequent fate. T cells that bind to self-antigens and those that display insufficient affinity for MHC are eliminated in the thymus. Meanwhile, T cells that show weak affinity for MHC-bound antigens (including self) are released into the blood and lymphoid organs as naive T cells. In these peripheral sites, naive T cells are exposed to professional APCs that provide the costimulatory signal that activates them. Here, the role of immune checkpoint pathways mediated by CTLA-4 and PD-1 plays a central role in immunoregulation by inhibiting the activity of T cells with an affinity for self-antigens.

Although binding of the TCR to MHC-bound antigen confers specificity to the T cell, its activation will require further costimulatory signals. Binding of B7 ligand on APCs to CD28 receptor on T cells leads to signaling within the T cell that results in its proliferation, differentiation, and survival. Regulation of this process is achieved through the binding of another receptor, CTLA-4 to B7. The amount of CD28:B7-to-CTLA-4:B7 binding governs whether the T cell will become activated or anergic. It is postulated that CTLA-4:B7 binding induces inhibitory signals that oppose activating signals from TCR:MHC and CD28:B7 binding.

A similar result is seen in the binding of PD-1 on T cells with PD-L1/2 on APCs. PD-1 is a marker of T-cell exhaustion, which when activated results in downregulation of T-cell function. This process has been observed in disease states such as chronic infection and cancer.

Both CTLA-4 and PDL-1 are members of the B7/CD28 superfamily of costimulatory receptors. Although the activation of both pathways induces negative effects on T-cell activity, they two differ in terms of timing of downregulation and the anatomic location where the activity of each receptor can be observed. The activity of CTLA-4 is observed during the priming phase of T-cell activation, whereas the activity of PD-1 occurs mainly during the effector phase. CTLA-4 binds to B7, which is found on APCs in the lymph nodes and the spleen. Meanwhile, PD-1 binds to PD-L1/2, which is more widely expressed, being found in lymphoid and non-lymphoid cells as well as in cancer cells. Therefore, its action is primarily seen in peripheral tissues.

Immune checkpoint inhibition and the challenge of predictive biomarkers

Currently, immune checkpoint inhibitors (ICIs) that target CTLA-4 or PD-1/PD-L1 signaling are used for the treatment of cancers. Solid tumors with approved indications for ICIs are metastatic melanoma, non-small-cell lung cancer (NSCLC), gastroesophageal or gastric cancer, hepatocellular carcinoma, microsatellite instability-high (MSI-H) colorectal cancer, head and neck squamous cell carcinoma, renal cell carcinoma (RCC), urothelial cell carcinoma, classical Hodgkin’s lymphoma, and metastatic Merkel cell carcinoma.

Pembrolizumab, a monoclonal antibody against PD-1, is one of the currently used ICIs. Its use in NSCLC is the only one guided by a biomarker – the tumor proportion score (TPS) of PD-L1 expression. In the first-line treatment of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutation-negative, NSCLC, the use of pembrolizumab is recommended if the tumor manifests a high PD-L1 expression defined as a TPS of at least 50%. In the second-line treatment and beyond, a minimum TPS of 1% is required. In addition, if the tumor is EGFR or ALK mutation positive, then the progression needs to have followed the treatment with the appropriate targeted agent. For mutation-negative tumors, progression needs to have followed the treatment with a platinum-based regimen. In contrast, there are no recommended PD-L1 expression levels for nivolumab, which is another anti-PD-1 monoclonal antibody.

The inability to estimate which patients will benefit from ipilimumab continues to be a source of consternation. CTLA-4 is an unreliable biomarker for response, and other markers that are possibly associated with outcomes in ipilimumab therapy such as absolute lymphocyte count, inducible costimulatory (ICOS) molecule, and NY-ESO-1 have been investigated; however, none of these have been validated.

Due to the lack of reliability and generalizability of PD-L1 and CTLA-4, the possible utility of other biomarkers...
such as professional immunoregulatory cells, soluble mediators such as adenosine, and, particularly, the NLR also warrant investigation and review.\textsuperscript{8,18}

**Neutrophils and inflammation**

Neutrophils exhibit heterogeneity of function in the tumor microenvironment, which can be categorized into two phenotypes—high-density neutrophils (HDNs) and low-density neutrophils (LDN). The HDN phenotype promotes antitumor effects either through direct action against tumor cells or by stimulating T-cell-mediated immunity. In contrast, the LDN phenotype favors tumor progression by promoting T-cell suppression through the expression of arginase and upregulating tumor angiogenesis through vascular endothelial growth factor (VEGF). Set against the backdrop of inflammation, neutrophils exhibit the HDN phenotype predominantly during the early phases of inflammation, whereas the LDN phenotype tends to accumulate when inflammation resolves.\textsuperscript{29,36,40}

Cancer can be viewed as a chronic inflammatory process, wherein HDNs are generated overtime. Notably, tumor-associated inflammation does not completely resolve due to the concerted effects of genetically altered tumor cells, hypoxia, and cell death. As a result, LDN neutrophils accumulate overtime, leading to an overall unfavorable neutrophil phenotype in the tumor microenvironment. Moreover, the proportion of LDN tends to increase in relation to tumor burden. It is of interest to note that in murine models, exposure of HDN to transforming growth factor (TGF)-\(\beta\) leads to a conversion to the LDN phenotype. TGF-\(\beta\) functions both as an effector cytokine in the resolution of inflammation and as a promoter of epithelial–mesenchymal transition (EMT), leading to tumor progression and metastasis.\textsuperscript{29,38,40,42}

**Professional immunoregulatory cells – myeloid-derived suppressor cells (MDSCs) and regulatory T cells (T\textsubscript{regs})**

Granulocyte myeloid-derived suppressor cells (gMDSCs) are closely related to neutrophils. This term describes a subset of myeloid cells expressing neutrophilic markers, such as human CD15 and CD66b, accompanied by a suppressive phenotype.\textsuperscript{15,33,55} These cells play an important role in tumor progression by the following mechanisms: 1) regulation of T-cell and natural killer (NK)-cell antitumor activity, 2) facilitation of tumor neovascularization, 3) assistance in tumor invasion of proximal and distal sites, and 4) enabling EMT.\textsuperscript{10,55}

Effector T cells, particularly those of cytotoxic (CD8\(^+\)) T cells, play a central role in the immune response to cancer; and the engagement of effector T cells and NK cells in the tumor microenvironment is the goal of successful immunotherapy.\textsuperscript{31,44} High-density infiltration of tumor by these cells has been associated with earlier tumor stage and a more favorable prognosis for patients.\textsuperscript{17,38} In contrast to cytotoxic T cells, T\textsubscript{regs} most commonly defined by their expression of a nuclear transcription factor, FOXP3, are thought to attenuate the immune response to cancer by suppressing the activity of cytotoxic T cells via cell-to-cell contact and the release of cytokines, notably TGF-\(\beta\). Conversely, the reduction of T\textsubscript{regs} in the peripheral blood of patients reinvigorates the immune response to tumor based on studies of colorectal cancer.\textsuperscript{5,38} However, recent studies have shown that T\textsubscript{regs} infiltration of tumors portends a more favorable prognosis in specific cancer types such as follicular lymphoma, diffuse large B-cell lymphoma, Hodgkin’s lymphoma, and even colorectal cancer, which possibly reflects the effect of the type of cancer involved and its respective microenvironment on the phenotype of the infiltrating T\textsubscript{reg}.\textsuperscript{16}

In addition, various studies attribute this phenomenon to the heterogeneity of T\textsubscript{regs}, showing the need to more specifically describe a given population beyond FOXP3 positivity alone.\textsuperscript{1,15,39,47,48} Although the definite role of T\textsubscript{regs} in the tumor microenvironment is unclear, the increased presence of T\textsubscript{regs} and MDSC in human tumors as well as in the circulation of patients with cancer has been widely described.\textsuperscript{48}

**Adenosine and tumor hypoxia**

Adenosine is a purine nucleoside, which affords a variety of functions depending on its action in the intracellular or extracellular compartment. Intracellularly, adenosine plays a role in cellular energetics, the methionine cycle, and the metabolism of nucleic acids. Meanwhile, extracellularly, it plays a role in immunoregulation.\textsuperscript{33,44} Extracellular adenosine exerts its effects by binding to one of the four G-protein-coupled adenosine receptors—A1R, A2AR, A2BR, and A3R. These receptors are subdivided based on their ability to induce downstream signaling via cAMP. Induction of cAMP signaling via A2AR and A2BR is associated with immunosuppression. In contrast, inhibition of cAMP signaling via A1R and A3R is associated with immunopromotion.\textsuperscript{45}

The action of the ectonucleotidases CD39 and CD73 enables the conversion of ATP to adenosine, which leads to its accumulation in the tumor microenvironment particularly in the setting of hypoxia. Low oxygen levels in the tumor microenvironment caused by an erratic tumor blood supply, high metabolic demand by the tumor, and even inflammation force cells in the tumor microenvironment to switch from an
aerobic to an anaerobic type of metabolism. This switch is facilitated by hypoxia-inducible factor-1α (HIF-1α). HIF-1α also induces CD39, CD73, and A2BR expression, thus promoting adenosine-mediated immunosuppression. Notably, this same process has been reversed in mouse models by whole body exposure to a hyperoxic atmosphere.\(^4\)\(^5\) Also, in murine studies, HIF-1α has also been found to increase tumor infiltration by FOXP3\(^+\) T\(_{reg}\)\(^3\)\(^4\)\(^5\).

NLR
Systemic inflammation is associated with prognosis in solid tumors.\(^2\)\(^4\)\(^27\)\(^37\)\(^49\)\(^52\)\(^54\) NLR is a marker for the general immune response to various stress stimuli.\(^18\)\(^20\)\(^37\) Studies have also correlated the NLR with other predictive biomarkers of outcomes in immune checkpoint blockade. The peripheral neutrophil count measured by the NLR has been found to be directly correlated with the intratumor neutrophil population.\(^29\) Studies have reported a direct correlation between NLR and intratumoral levels of gMDSCs.\(^19\)\(^33\) Finally, elevated levels of peripheral blood T\(_{reg}\) accompanied by an elevated NLR were associated with a poor prognosis for patients with pancreatic cancer.\(^8\)

Research question
In patients with cancer receiving ICI therapy, what is the utility of the NLR in predicting overall survival (OS) and progression-free survival (PFS)?

Methods
Search strategy and study selection
A systematic review was conducted to identify studies on the relationship of the NLR with OS and PFS in patients treated with ICIs. A search for relevant published and unpublished studies was performed using PubMed, ScienceDirect, Google Scholar, and the American Society of Clinical Oncology (ASCO) meetings library. The search terms utilized were NLR, immune checkpoint inhibitor response, prognosis, nivolumab, pembrolizumab, and ipilimumab. The last search was updated on June 24, 2017. Both free text and medical subheadings (MeSH) terms were used in the search strategy.

Included studies involved 1) human subjects receiving immune checkpoint inhibitor therapy for solid tumors and 2) determination of the relationship between baseline NLR and prognosis (OS and PFS).

Exclusion criteria were 1) absent baseline NLR values; 2) concomitant use of a chemotherapeutic agent with the ICI; 3) analysis of NLR in combination with other patient variables (eg, NLR + lactate dehydrogenase [LDH]); 4) reviews, letters, commentaries, case reports, expert opinions, and nonhuman studies; 5) incomplete or non-analyzable data; and 6) publication in a language other than English, which did not have an English translation.

Data extraction
All searches were conducted independently by the first two investigators. They independently extracted data on the authorship and publication history of the studies included. Data on cancer studied, NLR cutoffs, type of ICIs investigated, and the outcome measures used (hazard ratio [HR] with 95% CI) were also obtained from the included studies. Any discrepancy was resolved by consensus and in consultation with the third author.

Jeyakumar et al\(^24\)\(^25\) presented two reports with OS and PFS data for melanoma combined with genitourinary (GU) cancers\(^4\) (RCC and urothelial carcinoma [UC]), respectively. Both papers were presented as abstracts at the 2017 session of ASCO. Due to uncertainties regarding overlap for the data set on GU cancer, the authors of this meta-analysis decided to use only the data on melanoma from the first study and the data on GU cancers from the second study.\(^25\) No data for the ICI pembrolizumab were obtained, but a study\(^4\) that looked at patients receiving anti-PD-1 therapy (pembrolizumab or nivolumab) was included in this analysis.

Statistical analysis
Analysis of the relationship between NLR and prognosis in ICI therapy was performed according to the cancer site (melanoma, lung, and GU cancers) and the type of ICI used (ipilimumab, nivolumab, unspecified, or pooled). HRs with their 95% CIs from each study were used to calculate pooled HRs. Testing of heterogeneity of pooled results was performed using Cochran’s Q test and Higgins I\(^2\) statistic. A value of \(p<0.10\) for Q test was considered statistically significant, and the random-effects (DerSimonian-Laird method) model was applied to calculate the pooled HRs.\(^6\) Publication bias of literatures was evaluated using Begg’s funnel plot and Egger’s linear regression test, and a value of \(p<0.05\) was considered statistically significant. All statistical analyses were performed using Review Manager, version 5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark).

Results
Study characteristics
A total of seven articles were obtained using the inclusion and exclusion criteria outlined earlier. Figure 1 details the data extraction process undertaken by the authors. All included...
studies were published in English. Three studies were on melanoma, three studies were on NSCLC, one study was on GU cancers, and one study was on both melanoma and GU cancer (see Methods for how this was handled). Of the seven included studies, six were carried out in the United States and one was carried out in France. Only three studies reported on the ethnicity of their participants. Bagley et al described participants as Caucasian, African American, Asian, or others. Meanwhile, Jeyakumar et al described their participants as African American or other. Regarding the type of ICI used, two studies reported on ipilimumab, two studies reported on nivolumab; one study reported on pooled data from nivolumab and pembrolizumab, and the remaining two studies did not specify the type of ICI used.

Table 1 summarizes the characteristics of included studies.

### Risk of bias

Figure 2 summarizes the data for risk bias across included studies. All studies included were cohort studies. Five of the seven studies were of retrospective design that utilized registries to obtain patient data. None of the included studies reported on co-interventions given (eg, colony-stimulating factors for supportive care). Cancer stage and Eastern

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>197 Stage III and IV melanoma treated from 2006 to 2011</td>
<td>58 Stage III and IV unresectable melanoma treated from 2008 to 2014</td>
<td>175 advanced NSCLC treated outside a clinical trial from 2015 to 2016</td>
<td>115 NSCLC treated with nivolumab treated in a single institution Nivolumab</td>
<td>52 patients with advanced NSCLC treated in a single institution Nivolumab</td>
<td>84 patients with melanoma treated with immune checkpoint inhibitors ICI not specified</td>
</tr>
<tr>
<td>ICI</td>
<td>Ipilimumab (3 or 10 mg/kg q3 weeks for up to four doses)</td>
<td>Ipilimumab (3 or 10 mg/kg q3 weeks for up to four doses followed by maintenance)</td>
<td>Nivolumab (3 mg/kg every 2 weeks without concomitant treatment)</td>
<td>Nivolumab (N=48): pembrolizumab (N=4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NLR calculation</td>
<td>NLR calculated at baseline and q3 weeks until 9 weeks</td>
<td>NLR measured continuously, at weeks 1 and 7</td>
<td>NLR taken at baseline</td>
<td>NLR taken at baseline and after two cycles</td>
<td>NLR taken at baseline</td>
<td>NLR taken at baseline</td>
</tr>
<tr>
<td>NLR cutoff</td>
<td>≥5 and &lt;5 q4 and &lt;4 54.3 months OS and PFS</td>
<td>931 days OS</td>
<td>Not stated OS</td>
<td>Not stated OS and PFS</td>
<td>≥4.59 or ≤2.8 13.6 months OS and PFS</td>
<td>Not stated OS and PFS</td>
</tr>
<tr>
<td>Median follow-up</td>
<td>54.3 months OS and PFS</td>
<td>931 days OS</td>
<td>Not stated OS</td>
<td>Not stated OS and PFS</td>
<td>≥4.59 or ≤2.8 13.6 months OS and PFS</td>
<td>Not stated OS and PFS</td>
</tr>
<tr>
<td>Outcome of interest</td>
<td>HR for death, 2.03 (95% CI, 1.49–2.77); HR for progression, 1.81 (95% CI, 1.33–2.45)</td>
<td>HR for death, 2.07 (95% CI, 1.33–3.3); HR for progression, 1.43 (95% CI, 1.02–2.09)</td>
<td>HR for death, 1.09 (95% CI, 1.04–1.13; p=0.0002)</td>
<td>HR for death, 1.82 (p=203); HR for progression, 1.83 (p=0.06)</td>
<td>For NLR ≥4: HR for death, 3.133 (p=0.002); HR for progression, 1.58 (p=0.120)</td>
<td>For NLR ≥4: HR for death, 3.133 (p=0.002); HR for progression, 1.58 (p=0.120)</td>
</tr>
<tr>
<td>Study design</td>
<td>Prospective cohort</td>
<td>Retrospective cohort</td>
<td>Retrospective cohort</td>
<td>Prospective cohort</td>
<td>Retrospective cohort</td>
<td>Retrospective cohort</td>
</tr>
</tbody>
</table>

Abbreviations: GU, genitourinary; HR, hazard ratio; ICI, immune checkpoint inhibitor; NLR, neutrophil-to-lymphocyte ratio; NSCLC, non-small-cell lung cancer; OS, overall survival; PFS, progression-free survival; RCC, renal cell carcinoma; UC, urothelial carcinoma.
Sacdalan et al

OncoTargets and Therapy 2018:11

submit your manuscript | www.dovepress.com
dovepress

960

Oncometry Group (ECOG) score were reported across studies and assessment of outcomes factored these as well.

Outcomes of included studies

A high NLR resulted in worse OS (HR, 1.92; 95% CI, 1.29–2.87; p=0.001) and PFS (HR, 1.66; 95% CI, 1.38–2.01; p<0.0001). Subgroup analysis across types of malignancy treated with ICI is as follows: melanoma (HR, 2.18; 95% CI, 1.66–2.84; p<0.0001) and NSCLC (HR, 1.63; 95% CI, 0.92–2.88; p=0.09). The single study on GU cancers also showed worse OS (HR, 1.82; 95% CI, 0.68–4.84; p=0.23). High NLR also corresponded to worse PFS for melanoma (HR, 1.73; 95% CI, 1.33–2.25; p<0.0001) and NSCLC (HR, 1.56; 95% CI, 1.14–2.13; p=0.005). The single study on GU cancers also showed worse PFS (HR, 1.83; 95% CI, 0.97–3.44; p=0.06).

A high NLR also showed worse OS and PFS across all ICIs (OS: HR, 1.92; 95% CI, 1.29–2.87; p=0.001; PFS: HR, 1.66; 95% CI, 1.38–2.01; p<0.00001). Subgroup analysis by ICI showed similar results: for ipilimumab (OS: HR, 2.05; 95% CI, 1.54–2.04; p<0.00001; PFS: HR, 1.81; 95% CI, 1.33–2.45; p=0.0002) and worse OS for nivolumab (OS: HR, 1.43; 95% CI, 0.77–2.69; p=0.26; PFS: HR, 1.43; 95% CI, 1.02–2.00; p=0.04). For studies that did not specify ICI used and those that pooled nivolumab and pembrolizumab, OS and PFS showed similar results (OS: HR, 2.52; 95% CI, 1.58–4.02; p<0.0001; PFS: HR, 1.76; 95% CI, 1.25–2.47; p=0.001). Figures 3–6 summarize the outcomes of studies in this meta-analysis.

Heterogeneity

Significant heterogeneity was noted for pooled data on OS because of a single study. Heterogeneity diminished in pooled data on PFS since the same study did not report PFS data and hence was excluded. The χ² and I² showed that the null hypothesis of homogeneity was rejected as has been observed.

Risk of publication bias

Due to the retrospective nature of most studies included, the authors cannot determine whether selective reporting was performed in any of the articles reviewed.
### Table: HR for overall survival by NLR according to the tumor type.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Log (hazard ratio)</th>
<th>SE</th>
<th>Weight (%)</th>
<th>Hazard ratio IV, random (95% CI)</th>
<th>Hazard ratio IV, random (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Melanoma</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zaragoza et al.&quot; (2015)</td>
<td>0.7872</td>
<td>0.3966</td>
<td>11.6</td>
<td>2.20 (1.01, 4.78)</td>
<td></td>
</tr>
<tr>
<td>Jeyakumar et al.&quot; (2017)</td>
<td>1.142</td>
<td>0.3695</td>
<td>12.3</td>
<td>3.13 (1.52, 6.46)</td>
<td></td>
</tr>
<tr>
<td>Cassidy et al.&quot; (2017)</td>
<td>0.7088</td>
<td>0.1582</td>
<td>18.4</td>
<td>2.03 (1.49, 2.77)</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>42.3</strong></td>
<td></td>
<td></td>
<td>2.18 (1.66, 2.84)</td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: $\chi^2=1.16$, df=2 ($p=0.56$), $I^2=0%$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: $Z=5.69$ ($p&lt;0.00001$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Figure 3: HR for overall survival by NLR according to the tumor type.

**Abbreviations:** GU, genitourinary; HR, hazard ratio; M, melanoma; NLR, neutrophil-to-lymphocyte ratio; SE, standard error.

---

### Table: HR for progression-free survival by NLR according to the tumor type.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Log (hazard ratio)</th>
<th>SE</th>
<th>Weight (%)</th>
<th>Hazard ratio IV, random (95% CI)</th>
<th>Hazard ratio IV, random (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Melanoma</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeyakumar et al.&quot; (2017)</td>
<td>0.5988</td>
<td>0.4989</td>
<td>9.3</td>
<td>1.82 (0.68, 4.84)</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>9.3</strong></td>
<td></td>
<td></td>
<td>1.82 (0.68, 4.84)</td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: $Z=1.20$ ($p=0.23$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Figure 4: HR for progression-free survival by NLR according to the tumor type.

**Abbreviations:** GU, genitourinary; HR, hazard ratio; M, melanoma; NLR, neutrophil-to-lymphocyte ratio; SE, standard error.
Figure 5 HR for overall survival by NLR according to the immune checkpoint inhibitor.

Abbreviations: GU, genitourinary; HR, hazard ratio; M, melanoma; NLR, neutrophil-to-lymphocyte ratio; SE, standard error.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Log (hazard ratio)</th>
<th>SE</th>
<th>Weight (%)</th>
<th>Hazard ratio IV, random (95% CI)</th>
<th>Hazard ratio IV, random (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ipilimumab</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cassidy et al(17)</td>
<td>0.7088</td>
<td>0.1582</td>
<td>18.4</td>
<td>2.03 (1.49, 2.77)</td>
<td></td>
</tr>
<tr>
<td>Zarragoza et al(15)</td>
<td>0.7872</td>
<td>0.3966</td>
<td>11.6</td>
<td>2.20 (1.01, 4.78)</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>30</strong></td>
<td></td>
<td></td>
<td><strong>2.05 (1.54, 2.74)</strong></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: $\tau^2=0.00$; $\chi^2=0.03$, $df=1$ ($p=0.85$), $I^2=0%$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Test for overall effect: $Z=4.90$ ($p&lt;0.00001$)</td>
</tr>
</tbody>
</table>

| **Nivolumab** |                   |     |            |                                  |                                  |
| Bagley et al(17) | 0.7281            | 0.2376 | 16.1      | 2.07 (1.30, 3.30)               |                                  |
| Patil et al(17) | 0.0807            | 0.0212 | 20.6      | 1.08 (1.04, 1.13)               |                                  |
| **Subtotal (95% CI)** | **20**          |     |            | **1.43 (0.77, 2.69)**          |                                  |
| Heterogeneity: $\tau^2=0.18$; $\chi^2=7.37$, $df=1$ ($p=0.007$), $I^2=86\%$ | | | | | Test for overall effect: $Z=1.13$ ($p=0.26$) |

| **ICI – combined or unspecified** |                   |     |            |                                  |                                  |
| Jeyakumar et al(17) | GU | 0.5988 | 0.4989 | 9.3 | 1.82 (0.68, 4.84) |
| Jeyakumar et al(17) | M | 1.142 | 0.3695 | 12.3 | 3.13 (1.52, 6.46) |
| Soyano et al(17) | 0.8803 | 0.3959 | 11.6 | 2.41 (1.11, 5.24) |
| **Subtotal (95% CI)** | **33.3** |     |            | **2.52 (1.58, 4.02)**          |                                  |
| Heterogeneity: $\tau^2=0.00$; $\chi^2=0.79$, $df=2$ ($p=0.68$), $I^2=0\%$ | | | | | Test for overall effect: $Z=3.89$ ($p<0.00001$) |

**Total (95% CI):** 100 1.92 (1.29, 2.87)

Heterogeneity: $\tau^2=0.20$; $\chi^2=38.41$, $df=6$ ($p<0.00001$), $I^2=84\%$
Test for overall effect: $Z=3.20$ ($p=0.001$)
Test for subgroup differences: $\chi^2=1.99$, $df=2$ ($p=0.37$), $I^2=0\%$.

Figure 6 HR for progression-free survival by NLR according to the immune checkpoint inhibitor.

Abbreviations: GU, genitourinary; HR, hazard ratio; M, melanoma; NLR, neutrophil-to-lymphocyte ratio; SE, standard error.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Log (hazard ratio)</th>
<th>SE</th>
<th>Weight (%)</th>
<th>Hazard ratio IV, random (95% CI)</th>
<th>Hazard ratio IV, random (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ipilimumab</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cassidy et al(17)</td>
<td>0.5906</td>
<td>0.1558</td>
<td>38.1</td>
<td>1.81 (1.33, 2.45)</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>38.1</strong></td>
<td></td>
<td></td>
<td><strong>1.81 (1.33, 2.45)</strong></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Test for overall effect: $Z=3.79$ ($p=0.0002$)</td>
</tr>
</tbody>
</table>

| **Nivolumab** |                   |     |            |                                  |                                  |
| Bagley et al(17) | 0.3565            | 0.1718 | 31.4      | 1.43 (1.02, 2.00)               |                                  |
| **Subtotal (95% CI)** | **31.4**          |     |            | **1.43 (1.02, 2.00)**          |                                  |
| Heterogeneity: not applicable | | | | | Test for overall effect: $Z=2.08$ ($p=0.04$) |

| **ICI – combined or unspecified** |                   |     |            |                                  |                                  |
| Soyano et al(17) | 0.7345            | 0.3261 | 8.7 | 2.08 (1.10, 3.95) |
| Jeyakumar et al(17) | GU | 0.6043 | 0.3213 | 9.0 | 1.83 (0.97, 3.44) |
| Jeyakumar et al(17) | M | 0.4174 | 0.2685 | 12.8 | 1.52 (0.90, 2.57) |
| **Subtotal (95% CI)** | **30.5**          |     |            | **1.76 (1.25, 2.47)**          |                                  |
| Heterogeneity: $\tau^2=0.00$; $\chi^2=0.59$, $df=2$ ($p=0.75$), $I^2=0\%$ | | | | | Test for overall effect: $Z=3.23$ ($p=0.001$) |

**Total (95% CI):** 100 1.66 (1.38, 2.01)

Heterogeneity: $\tau^2=0.00$; $\chi^2=1.74$, $df=4$ ($p=0.78$), $I^2=0\%$
Test for overall effect: $Z=5.29$ ($p<0.00001$)
Test for subgroup differences: $\chi^2=1.16$, $df=2$ ($p=0.56$), $I^2=0\%$. 

Figure 6 HR for progression-free survival by NLR according to the immune checkpoint inhibitor.

Abbreviations: GU, genitourinary; HR, hazard ratio; M, melanoma; NLR, neutrophil-to-lymphocyte ratio; SE, standard error.
Discussion

Inflammation has been seen to play a critical role in tumor development. Specifically, it has been observed to have a detrimental effect on patient survival in cancer. Increasing NLR has been demonstrated to be a harbinger of a more dismal prognosis across different cancers.\(^{2,4,27,37,49,51–55}\) The utility of NLR lies in its ability to reflect the degree of inflammation present in a patient.\(^{27,24}\)

This meta-analysis aims to study the effectiveness of this biomarker in the prediction of prognosis among patients receiving ICI. Although including relatively few studies, this review has shown that across several cancer types, and at least between the ICIs, ipilimumab and nivolumab and based on the pooled data from nivolumab and pembrolizumab, NLR is a potentially useful prognosticating tool. It is particularly advantageous because of its availability and noninvasive nature.

However, NLR is not without its criticisms. To begin, the lack of a uniform cutoff value among studies shows that the understanding of this biomarker is still immature, and this observation has also been made by other authors.\(^{14,30}\) Although a high NLR value is clearly detrimental, it is uncertain what value of NLR is ideally used to estimate prognosis across ICI-treated patient groups. In addition, NLR is a dynamic marker, varying across time points during a patient’s treatment course. While this review has looked at the prognostic utility of baseline NLR values, other studies have also looked at the change in NLR during treatment as another potential prognostic tool.\(^{7,12,26}\) Whether a single NLR determination or several over a time course is better at estimating prognosis in ICI-treated patients has not been established.

By showing that NLR can predict outcomes in ICI-treated patients, this study supports the idea that inflammation, through different mediators, attenuates the effectiveness of immune checkpoint blockade. Furthermore, it presses the need to search for potentially targetable mediators of inflammation in patients treated with ICIs as suggested by other authors.\(^{28}\) Targeting these pro-inflammatory molecules may, in turn, directly affect patient outcomes.

We put forward several points for future research focus. First, methods employed in study inclusion may be a source of bias because not all studies on ICI routinely report on NLR data, which impacts the robustness of the analysis performed here. Second, most of the included studies were of retrospective design. Data collected from registries are prone to unintentional (missing data) or even intentional bias (patients being left out of reporting).\(^{32}\) Third, the effects of co-interventions (eg, colony-stimulating factors for supportive care) and confounders (eg, timing of treatment) are difficult to account for.

Finally, it is worth noting that the weight of study-level data as used in this analysis may not be the same as that of patient-level data due to the latent effects the respective analyses already applied to them. Nevertheless, the results of this study show that NLR is an effective tool in prognosticating patients treated with ICIs.

Conclusion

In this meta-analysis, we have shown that a high NLR is associated with poorer outcomes across studies of ICI-treated patients. This shows that NLR has the potential to be a readily available prognostic indicator for patients receiving ICI based on available studies. Further research will allow better understanding of this biomarker and its role in the use of ICIs in cancer.

Areas for further research

- We recommend that NLR be measured in succeeding therapy trials to aid in future analysis.
- Determination of a standardized cutoff for NLR values is worth investigating.
- Utility of baseline NLR coupled with changes in NLR in a prospective setting to better elucidate the value of NLR in prognosticating outcomes in ICI-treated patients.

Disclosure

The authors report no conflicts of interest in this work.

References


